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Abstract
The management of acute lymphoblastic leukemia is a challenge in patients of 
any age range. In the elderly patient, this challenge is further complicated by having 
to take into account the physical, social, psychological, and emotional factors of this 
age group, which, together with the complex nature of the disease’s biology, give rise 
to many questions. Although the diagnostic approach of the disease does not differ 
from that performed in pediatric or young patients, it does in the determination of 
risk factors and treatment, since many of the determinants of risk have a different 
value to that assigned in other patients, and, therefore, we cannot apply all available 
resources in younger patients to facilitate our work. The genetic alterations of ALL 
are found more frequently in elderly patients, since age is a factor that increases 
the risk of presenting these alterations. As an example, the prognostic value of the 
presence of Philadelphia chromosome (t (9:22)) cannot be weighted at the same scale 
as in pediatric patients. Comorbidities play another important role when it comes to 
making therapeutic decisions, and there is currently controversy regarding the use of 
scores designed to determine the physical and physiological status of elderly subjects. 
Several analyzes have been carried out to define the value and usefulness of these 
tools in the older patients with ALL; however, work must still be done in this area. The 
treatment schemes should be adjusted to the needs and specific characteristics of each 
individual in advanced age. The use of intensive chemotherapy should be discussed 
within a multidisciplinary team, always considering the benefit of our patients. In the 
present chapter, the diverse differences in ALL biology will be addressed when com-
pared with those of children and young adults, and with the impact on the different 
prognostic determinants and their weight at the time of deciding treatment. The need 
to apply geriatric tools for decision-making and the therapeutic schemes used around 
the world for elderly people will also be discussed.
Keywords: acute lymphoblastic leukemia, long-term survival, older adults, 
remission, leukemia-free survival, overall survival, death
1. Introduction
Acute lymphoblastic leukemia (ALL) is a rare disease in the elderly. The preva-
lence of ALL in patients >60 years of age is reported to be between 16 and 31% of all 
adult cases. In adults, it represents approximately 20% of all leukemia [1].
The age-adjusted incidence rate of ALL in the United States is 1.58 for every 
100,000 persons per year. About 57.2% of the patients diagnosed are under 20 years 
of age, 26.8% of patients diagnosed are over 45 years of age, and 11% of patients 
diagnosed are over 65 years of age [2]. The biology of ALL in older patients seems 
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to be significantly different from that in younger patients and may, at least in 
part, explain the poor treatment outcome. Immunophenotyping and cytogenetic 
characteristics are among the most important biological differences in comparison 
with younger adults. The frequency of pre-B-cell ALL and common ALL is higher, 
and T-cell ALL subtype is under-represented in elderly populations compared with 
younger patients. The frequency of the Philadelphia chromosome also seems to 
increase with age and adversely influences complete remission rate and survival. 
Few reports on the effectiveness and toxicity of therapeutic programs concerning 
exclusively older patients with ALL have been published so far and only some of 
them were prospective studies [3].
In some of the studies, age-adapted approaches have been applied in which 
protocols processed earlier for younger patients have been adopted for older 
patients. In such modified protocols, chemotherapy was usually less aggressive, 
especially if it was given for patients with comorbidities and poor performance 
status. Consequently, in several studies, elderly patients received suboptimal treat-
ment. Death during induction chemotherapy was observed in 7–42% of the patients 
in particular reports. The overall response rate varied from 12 to 85%. The median 
overall survival (OS) durations in patients who received a curative approach ranged 
from 3 to 14 months and from 1 to 14 months in patients treated with palliative 
therapy. Poor performance status, comorbidities, and high early mortality during 
intensive chemotherapy are the main reasons for poor treatment results and short 
OS time. New therapeutic approaches are necessary to improve the outcome in this 
age group of patients with ALL [4].
The implementation of tools aimed to determining the safety of treatments in 
elderly patients based on protocols that have previously been applied and validated 
in younger patients is a common practice today. A recently identified problem when 
applying these tasks is the underutilization of treatments with curative purposes in 
this group. An example of this is the CIRS-G scale, widely used to determine the risk 
of complications in patients with various comorbidities [4]. This phenomenon has 
been recorded in various efficacies and safety analyzes of treatment for acute lympho-
blastic leukemia in elderly patients based on similar scales, where an important sur-
vival difference has been observed between the groups treated for curative purposes 
and those who received reduced therapy. Of course, comorbidities play an important 
role in these poor results, which forces us to search for new therapeutic options [5].
The clonal origin of ALL has been established using cytogenetic analysis; 
restriction fragment analysis in female patients, which are heterozygous for 
polymorphic genes linked to the X chromosome; and analysis of T-cell receptor or 
immunoglobulin gene rearrangements. The clinical manifestations are very variable 
and insidious. The symptoms generally reflect bone marrow failure characterized 
by four syndromes: anemia, hemorrhage, febrile, and infiltrative. Nearly, half of 
the patients present with some kind of infectious process at diagnosis. Bone infiltra-
tion may produce pain and arthralgia. Additionally, close to half the patients have 
hepatomegaly or splenomegaly [5].
The long-term survival of older adults with acute lymphoblastic leukemia (ALL) 
who are intensively treated is about 40% [1]. Hematologic remissions are obtained 
in over 90% of patients, and the depth of these remissions using flow cytometry 
and molecular techniques is the subject of current studies. It is likely that, with 
time, new response definitions based on these tests will be established. The adult 
patients were divided into age 30 years and 30–60 years, because this seemed clini-
cally relevant, and available data best dealt with these age categories.  
However, these divisions are not absolute or evidence-based, and an individual’s 
biologic age and general fitness are of paramount importance. There are no ran-
domized studies in older adults that demonstrate “pediatric” approaches to be 
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superior, and indeed, the single-arm studies are still small scale in this age group, 
with insufficient follow-up. Much is unknown, but the wide variety of trials being 
conducted in adults with ALL is heartening [6].
2. Physiopathology
The development of ALL is driven by successive mutations that alter cellular 
functions promoting
• greater ability for self-renewal,
• greater proliferation,
• blockage of differentiation, and
• resistance to apoptotic signals.
Different hereditary DNA repair disorders can play an important role in the 
induction of this disease. Furthermore, mutagenic environmental agents, which can 
be physical (ionizing radiation), chemical (benzene), and biological (HTLV-1), can 
also be involved. However, in most cases, there are no identifiable etiologic agents. 
The precise pathogenic events that lead to the development of ALL are unknown. 
About 5% of the cases are associated with genetic predisposition syndromes. This 
is the case for children with Down syndrome, who have a 10–30 times greater risk 
of leukemia and present genetic abnormalities such as hyperdiploidy and t (12; 21) 
[ETV6-RUNX1], +X, del (9), and alteration in CCAAT//enhacer-binding protein 
beta (CEBPD). It has been demonstrated that the fusion of P2RY8-CRLF2 and the 
activation of JAK mutations contribute to 50% of the ALL cases in patients with 
Down syndrome. Ninety percent have a deletion of IKZF12015. The disorders associ-
ated with chromosomal fragility that have been found to predispose to ALL include 
ataxia-telangiectasia, Nijmegen syndrome, and Bloom syndrome [7]. Patients with 
ataxia-telangiectasia have 70 times greater risk of leukemia and 250 times greater 
risk of lymphoma, particularly of T cells. The causal gene, ataxia-telangiectasia 
mutated (ATM), encodes a protein implicated in DNA repair and regulation of 
cellular proliferation and apoptosis [2, 7, 8]. Complete genome sequencing studies 
have identified a number of common allelic variants in four genes (IKZF1, ARID5B, 
CEBPE, and y CDKN2A) associated with infant ALL. The allelic variant inherited 
can affect the response to treatment. In utero exposure to X-rays for diagnostic 
use can confer a slight increase in risk for ALL, which positively correlates with 
exposure intensity. Data exist that support a causal role for polymorphisms in genes 
that encode antioxidant enzymes (for example: glutathione S-transferase, nicotin-
amide adenine dinucleotide phosphate (NADPH), quinone oxidoreductase), folate 
metabolic enzymes (serine hydroxymethyltransferase and thymidylate synthase), 
cytochrome 450, methylenetetrahydrofolate reductase, and cell cycle inhibitors [3, 
5, 8, 9]. Specific fusion genes have been identified in leukemia, the most noteworthy 
being KMT2A/AFF1 (also known as MLL-AF4) and ETV6-RUNX1 or TEL-AML1; 
additionally, there is hyperploid and rearrangements of immunoglobulin or T-cell 
receptor genes. The acquired genetic anomalies are a hallmark, 80% of all cases 
contain cytogenetic or molecular lesions with abnormalities in chromosome number 
(ploidy) and structure. The mechanisms involved include aberrant expression of 
oncoproteins, loss of tumor suppressor genes, and chromosomal translocations, 
which generate fusion genes that encode transcription factors of active kinases. A 
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single genetic rearrangement is not enough to induce leukemia. Cooperative muta-
tions are necessary for leukemic transformation and include genetic and epigenetic 
changes in regulatory growth pathways. Candidate genes identified include deletion 
of the tumor suppressor locus CDKN2A/CDKN2B and NOTCH1 mutations in T 
cells. The use of single nucleotide polymorphism (SNP) microarrays suggests that 
genomic instability is not characteristic of most cases. There is a great variation 
in the number of alterations in different subtypes of leukemia. The infant cases 
with rearrangements of the MLL gene had less than one copy number alterations 
(CNA) per case, suggesting that few genetic lesions are required. Conversely, cases 
with ETV6-RUNX1 [25] and BCR-ABL1 had more than six CNAs, some containing 
more than 20 lesions, which support the concept that despite the initiating events 
that may occur in early infancy, additional lesions are required for the subsequent 
development of ALL. The lymphoid transcription factor PAX5 encodes a protein 
involved in evolution and fidelity of the B-cell lineage. The second most frequently 
affected gene was IKZF1, which encodes the protein IKAROS, required for lymphoid 
differentiation. IKZF1 is absent in most cases with BCR-ABL1. Approximately, half 
of the patients expressing BCRABL1 also had deletions in CDKN2A/B and PAX5. 
This finding suggests that alterations in different signaling pathways are needed to 
induce leukemia [15]. A special role in this disease is played by the presence of the 
Philadelphia chromosome t (9; 22), which expresses the BCR-ABL fusion gene, and 
this has diagnostic, prognostic, and therapeutic implications [3, 6–11].
3. Morphologic diagnosis
The bone marrow aspiration test is fundamental to confirm the presence of 
lymphoblasts (by morphology and/or cytochemistry with special stains that include 
a negative MPO in 100% of cells, Periodic Acid-Shiff  (PAS) (+) in 70–80%, and 
acid phosphatase (+) in the case of T lymphoblast). The WHO suggests greater than 
20% as diagnosis criteria (if the percentage is lower, one must search for extramed-
ullary disease at the nodal level to differentiate from the diagnosis of lymphoblastic 
lymphoma). The bone marrow aspiration is hypercellular 95–100% of the time; 
however, in those cases where the aspirate is “dry” (packed bone marrow), which 
corresponds to 1–2% of the cases, a bone biopsy must be carried out for histopatho-
logical confirmation. Based on morphology, the French-American-British (FAB) 
classification identifies three types of ALL [7, 8, 12].
The first step to integrate the diagnosis of ALL is the morphological identification 
of lymphoblasts. For this, it is necessary to perform a bone marrow aspirate and be 
observed directly under a microscope by an expert in hematology, which can be sup-
ported in other tests like special stains, as in the case of myeloperoxidase, which must 
be negative in all the malignant cells observed; PAS staining, which is considered 
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positive for ALL when observed in 70–80% of cells with malignant morphology and 
acid phosphatase, which is used for T-cell differentiation. Regarding manual cell 
counting, it is necessary that the presence of 20% or more cells with malignant char-
acteristics, as indicated by the criteria of the WHO classification, in case this criterion 
is not met, can be replaced by others such as the documentation of extramedullary 
disease. It is important to specify that most of the times, we may have difficulties in 
trying to obtain the sample for the bone marrow aspirate, since the large number of 
cells within the medullary space condition the presence of the phenomenon of “dry” 
aspiration; in these cases, we must carry out bone biopsy in a mandatory manner.
3.1 Images ALL
The French-American-British (FAB) classification that was used commonly 
earlier includes:
• L1—around 25–30% of adult cases and 85% of childhood cases of ALL are of 
this subtype. In this type, small cells are seen with:
 ○ regular nuclear shape
 ○ homogeneous chromatin
 ○ small or absent nucleolus
 ○ scanty cytoplasm
• L2—around 70% of adult cases and 14% of childhood cases are of this type. 
The cells are large and/or have varied shapes with:
 ○ irregular nuclear shape
 ○ heterogeneous chromatin
 ○ large nucleolus
• L3—this is a rarer subtype with only 1–2% cases. In this type, the cells are large 
and uniform with vacuoles (bubble-like features) in the cytoplasm overlying 
the nucleus.
In an initial effort, the French-American-British (FAB) was given the task of sub-
classifying this type of leukemia according to various morphological characteristics in 
order to try to determine the behavior and prognosis of each type based on its mor-
phology; this is how the FAB morphological classification was born, which subdivides 
the ALL into three types:
• L1: this subtype is characterized by presenting cells with a regular nucleus, 
homogeneous chromatin, small or absent nucleoli, and scarce cytoplasm. It 
represents the majority of the ALL in children observed in up to 85%, while in 
adults, it is seen between 30% and 70% of the times.
• L2: unlike the previous one, this subclassification is seen mostly in adults 
(70%) and its morphology is opposite to L1: chromatin is heterogeneous, the 
nucleus irregular, and with multiple nucleoli.
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• L3: the least frequent of the three, is reported between 1 and 2% of the time. Its 
main characteristic is the large number of vacuoles (bubbles) that these cells 
present in their cytoplasm. The shape of the nucleus may vary.
3.2 Revised version of FAB
WHO proposed a classification of ALL that was to be the revised version of the 
FAB classification.
This used the immunophenotypic classification that includes:
• Acute lymphoblastic leukemia/lymphoma or formerly L1 and L2 this has sub-
types including:
 ○ precursor B acute lymphoblastic leukemia/lymphoma: this has genetic 
subtypes including t(12,21)(p12,q22) TEL/AML-1, t(1,19)(q23;p13) PBX/
E2A, t(9,22)(q34;q11) ABL/BCR and T(V,11)(V;q23) V/MLL
 ○ precursor T acute lymphoblastic leukemia/lymphoma
• Burkitt’s leukemia/lymphoma or formerly L3
• biphenotypic acute leukemia
The WHO performed a new categorization of acute lymphoblastic leukemia, 
based on cytogenetic alterations present in this disease. This classification consid-
ered what was previously described in the FAB classification being possible to make 
an indirect correlation between the morphological findings and the alterations 
listed in the categories of the WHO classification. In this way, those leukemias that 
are traditionally classified in the FAB groups L1 and L2 can belong to the group of 
leukemia of precursors B with alterations such as: t (12; 21) (p12, q22) TEL/AML-1, 
t (1; 19) (q23; p13) PBX/E2A, t (9; 22) (q34; q11) ABL/BCR, and T (V, 11) (V; q23) 
V/MLL. Those traditionally classified as FAB L3 correlate with Burkitt’s leukemia/
lymphoma; T-cell leukemias are still an independent group and are considered 
another group where those that meet criteria for two different lineages are included.
4. Lineage
The proportion of B-lineage ALL is higher in patients older (75–89%) than 
60 years compared to patients younger (59–66%) than 60 years. Accordingly the 
incidence of T-ALL is lower in older (8–12%) compared to younger (29%) patients 
[5–7]. A population-based study showed that cytogenetics were less frequently 
attempted in older (73%) compared with younger (85–91%) patients. The proportion 
of patients with Philadelphia chromosome positive (Ph+) t(9;22), t(8;14), t(14;18), 
or complex aberrations increased with age [11]; Ph+ ALL accounted for 24–36% in 
older patients vs. 15–19% in younger patients. Considering the consequences resulting 
from diagnostic characterization, it should be self-evident that complete diagnostic 
characterization is required in all patients with ALL, regardless of age [13, 14].
There are several important differences in the biology of lymphoblastic leukemia 
in patients over 60 years compared to those under this age, although we know that 
B-lineage leukemia is the most common in adults, the frequency between both groups 
can vary reporting a little more frequent in those over 60 years (75–89%/59–66%), 
another more radical difference is the presentation of leukemia of T lineage, which is 
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more common in adults under 60 years (29%) than in elderly patients (12%) [5–7]. 
Cytogenetic alterations of importance for the prognosis, such as Philadelphia chromo-
some (Ph+) t (9; 22), t (8; 14), t (14; 18), or complex karyotype are observed more 
frequently as the patient’s age increases [11]. Although the search for cytogenetic altera-
tions is crucial to define the risk and possible response to treatment of acute leukemia, 
this analysis is not carried out in most elderly patients (73%), contrary to the young 
patients, who have available cytogenetic studies in up to 91%. The importance of this 
difference lies in the fact, already mentioned, of the increase in the frequency of high-
risk alterations, as an example Ph+ ALL can be found in up to 36% of cases, which have 
different therapeutic approaches to those that do not suffer from this alteration [13, 14].
As in other B-cell malignancies, monoclonal antibodies to CD20 or CD228 are 
being tested as adjuncts to chemotherapy in the hope that they will increase remis-
sion depth and improve survival without increasing hematologic toxicity. About 
60–80% of B-cell ALL patients express these antigens at variable densities, but 
there is little evidence linking antigen expression to response. CD20 expression may 
be associated with a worse prognosis, so it is logical to investigate CD20 antibodies 
in randomized trials, and it may improve the outcome [15, 16].
4.1 Immunophenotyping
Blasts in pre-B ALL can be initially identified using an SSC vs. a CD45 plot. 
These blasts have low SSC (many times smaller than normal lymphocytes) and dim 
to negative CD45.
Once the blasts are identified and gated, the following markers are useful in the 
classification of pre-B ALL:
Marker Prevalence
CD10 89%
CD13 5%
CD19 100%
CD20 24%
CD22 69%
CD33 31%
CD34 76%
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Included are marking prevalences.
The phenotype of the blasts is an independent prognostic parameter. B-ALL is 
subdivided into following:
• Early Pre-B ALL: TdT+, CD19+, CD10-
• Common ALL: CD19+, CD10+/CALLA+
• Pre-B ALL: CD10+/−, CD19+, HLA DR+, cytoplasmic IgM+
• Mature B ALL: CD10+, CD19+, CD20+, CD22+, surface IgM+
4.2 Immunophenotype of T-lineage ALL
T-cell ALL constitutes approximately 25% of all adult cases of ALL. T-cell mark-
ers are CD1a, CD2, CD3 (membrane and cytoplasm), CD4, CD5, CD7, and CD8. 
Marker Prevalence
CD45 (bright) 2%
CD45 (moderate) 33%
CD45 (dim) 36%
CD45 (negative) 29%
CD56 36%
CD79a 88%
CD117 0%
Cytoplasmic IgM 22%
HLA Dr 98%
TdT 91%
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CD2, CD5, and CD7 antigens are markers of the most immature T cells , but none of 
them is absolutely lineage-specific, so that the unequivocal diagnosis of T-ALL rests 
on the demonstration of surface/cytoplasmic CD3. In T-ALL, the expression of CD10 
is quite common (25%) and not specific; CD34 and myeloid antigens CD13 and/or 
CD33 can be expressed too. Recognized T-ALL subsets are the following: pro-T EGIL 
T-I (cCD3+, CD7+), pre-T EGIL T-II (cCD3+, CD7+, and CD5/CD2+), cortical T EGIL 
T-III (cCD3+, CD1a+, and sCD3+/−), and mature-T EGIL T-IV (cCD3+, sCD3+, and 
CD1a−). Finally, a novel subgroup that was recently characterized is represented by 
the so-called ETP-ALL (early-T precursor), which shows characteristic immunophe-
notypic features, namely lack of CD1a and CD8 expression, weak CD5 expression, 
and expression of at least one myeloid and/or stem cell marker [17].
4.3 Mixed phenotype acute leukemia
With currently refined diagnostic techniques, the occurrence of acute leu-
kemia of ambiguous cell lineage, i.e., mixed phenotype acute leukemia (MPAL) 
is relatively rare (<4%) [19]. These cases express one of the following feature: 
(1) coexistence of two separate blast cell populations (i.e., T- or B-cell ALL plus 
either myeloid or monocytic blast cells), (2) single leukemic population of blast 
cells co-expressing B- or T-cell antigens and myeloid antigens, and (3) same plus 
expression of monocytic antigens. For myelo-monocytic lineage, useful diagnostic 
antigens are MPO or nonspecific esterase, CD11c, CD14, CD64 and lysozyme; 
for B-lineage, CD19 plus CD79a, cytoplasmic CD22 and CD10 (one or two of the 
latter according to staining intensity of CD19); and for T-lineage, cytoplasmic 
or surface CD3. Recognized entities include Ph+ MPAL (B/myeloid or rarely T/
myeloid), t(v;11q23); MLL rearranged MPAL, and genetically uncharacterized B 
or T/myeloid MPAL. Very rare cases express trilineage involvement (B/T/myeloid). 
Lack of lineage-specific antigens (MPO, cCD3, cCD22) is observed in the ultrarare 
acute undifferentiated leukemia. In a recent review of 100 such cases, 59% were B/
myeloid, 35% T/myeloid, 4% B/T lymphoid, and 2% B/T/myeloid. Outcome was 
overall better following ALL rather than AML therapy [7, 16, 18, 19].
4.4 NK cell ALL
CD56, a marker of natural killer (NK) cell differentiation, defines a rare 
subgroup of about 3% of adult ALL cases, which often display other early T-cell 
antigens, CD7 CD2 CD5, and sometimes cCD3. True NK ALL is very rare (TdT+, 
CD56+, other T markers negative, and un-rearranged TCR genes). This diagnosis 
rely on the demonstration of early NK-specific CD94 or CD161 antigens [18, 19].
4.5 Diagnostic cytogenetics
Cytogenetics represents an important step in ALL classification. Conventional 
karyotyping can be helpful in the identification of recurrent translocations, as 
well as gain and loss of gross chromosomal material; however, the major limita-
tion of this technique is that in some cases, leukemic cells fail to enter metaphase. 
However, fluorescence in situ hybridization (FISH) can enable the detection and 
direct visualization of virtually all investigated chromosomal abnormalities in ALL, 
with a sensitivity of around 99%. Finally, array-comparative genomic hybridiza-
tion (array-CGH, a-CGH) and single nucleotide polymorphisms (SNP) arrays can 
permit the identification of cryptic and/or submicroscopic changes in the genome. 
Karyotype changes found in ALL include both numerical and structural alterations, 
which have profound prognostic significance. With these premises in mind, the 
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karyotype changes that occur in ALL can be roughly subdivided in those associated, 
respectively, with a relatively good, intermediate, and poor prognosis. However, it 
must be kept in mind that the incidence of certain aberrations is very low, and that 
for some of them, the prognostic impact can be strongly affected by the type and 
intensiveness of therapy administered [8, 20].
5. Clinical status
Features associated with large tumor mass or rapid progression, such as high white 
blood cell count, mediastinal tumors, or other organ involvement, appear to be less 
common in older patients. Even “smoldering” ALL is observed in some cases. Most 
studies report a lower proportion of males among older ALL patients. Secondary ALL 
after myelodysplastic syndromes or other malignant disease may become increas-
ingly important, particularly in older patients; so far, very limited data are available. 
Performance status often deteriorates in older patients with onset of disease. In two 
studies, 30–43% of patients older than age 60 years vs. 18–22% of younger patients 
had a performance status of 2 or more. Therefore, it is important not only to consider 
the current general condition in newly admitted older ALL patients but also to discern 
their status before the onset of leukemia-associated symptoms [17, 21].
The determination of the clinical status at the moment of making the diagno-
sis provides us with information about the global state of the patient, so that we 
can make better decisions. This varies in comparison with the younger groups in 
questions such as the low initial presentation of large tumor mass, identified by the 
elevated white blood cells count in the peripheral blood, the rare extranodal affec-
tion and even in some cases being observed, apparently “benign” clinical presenta-
tion with low tumor burden. A smaller proportion of male patients in this group 
have also been observed as compared with younger groups. Secondary leukemia, 
which we define as that which occurs after a premalignant pathology, most fre-
quently myelodysplastic syndrome, or after treatment of nonhematological neo-
plasms, is a condition that has been observed more and more frequently in recent 
years. However, there is little data to help us determine its nature. It is important 
to assess these patients comprehensively in order to determine their physical and 
health status prior to the onset of symptoms related to leukemia [17, 21].
6. Comorbidity
Of older ALL patients, 60–70% suffer from comorbidities, but most studies 
did not refer to validated scoring systems. The German multicentre study group 
for adult ALL (GMALL) identified comorbidities according to the Charlson score 
in 84% of the patients older than 55 years, with diabetes (46%), vascular disease 
(18%), heart failure (15%), and chronic lung disease (12%) being the most 
frequent. In addition, renal insufficiency, anemia, osteoporosis, dementia, and 
depression are probably the most relevant comorbidities for potential adjustment of 
treatment. About 8–16% had a history of prior malignant disease. I recommend a 
systematic evaluation and documentation of comorbidities based on a checklist or a 
score, since this is essential for planning an optimal treatment strategy [4, 5, 18, 23].
Comorbidities in elderly patients with ALL require a specialized and detailed 
approach. The German multicentre study group for adult ALL (GMALL) recom-
mends the use of the Charlson scale for the determination of risk due to comorbidi-
ties; this assessment must be done in an integral manner, together with the physics, 
biochemistry, and cytomolecular evaluation of the disease [4]. Multiple systemic 
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diseases can afflict elderly patients with ALL: diabetes, hypertension, heart failure, 
and renal failure are some of the most frequently reported in the various studies 
conducted. Age-specific conditions such as dementia or osteoporosis that can nega-
tively impact the patient’s performance before and after treatment should not be left 
aside. It is also important to evaluate, monitor and, if necessary, treat alterations 
in the emotional state of the elderly patient, since depression and anxiety are not 
infrequent conditions in this group [5, 18, 22].
7. Prognostic factors in older ALL patients
Now, we have a better understanding of the factors that determine survival, 
but these will require reexamination as we introduce novel therapies. Cytogenetic 
findings such as Philadelphia chromosome positivity, t (4; 11), complex cytogenetic 
abnormalities (more than five chromosomal changes), and low hypodiploidy/near 
triploidy result in inferior survival. Some of these changes are more common in older 
adults. Other conventional factors such as increasing age, high white blood cell count, 
and B-cell disease (rather than T-cell disease) still hold true and predict higher failure 
rates with standard chemotherapy. However, many of these factors are also associated 
with a higher relapse rate after allografting, and it is not necessarily the case that bone 
marrow transplantation (BMT) is the solution for patients with adverse prognostic 
features. Combining these factors may allow individualization of therapy, a prospect 
not previously possible in this rare condition. As well as undertreating patients with 
ALL with chemotherapy that is likely to fail, prognostic factors should be used to 
avoid over treating better prognosis patients with allogeneic transplants that have 
a high upfront risk and may result in chronic graft-versus host disease (GVHD), infer-
tility, and secondary malignancy. Chemotherapy and transplant have complementary 
roles in ALL management, and a pragmatic approach is required to deliver the best 
outcomes. The role of BMT is likely to increase, especially with the promising results 
of reduced-intensity allografting, but conversely, the use of BMT should be reduced if 
advances in nontransplant therapy improve cure rates [11, 17, 20, 23].
Increasing age itself is one of the most relevant prognostic factors for outcome 
of ALL from childhood to old age. Since older patients show opposite problems, 
namely higher mortality and relapse rates, prognostic factors for both have to be 
analyzed. Prognostic factors for relapse risk in younger ALL patients are probably 
also valid in older patients, such as early and mature T-ALL, pro-B ALL, elevated 
white blood cell count, and Ph+ ALL; however, their predictive value is somewhat 
diluted by mortality risks. Evaluation of minimal residual disease (MRD) has 
demonstrated that persistence of MRD is associated with a relapse rate above 90% 
in younger patients despite continued intensive chemotherapy. Few data on the 
prognostic impact of MRD are available in older patients. In one study, only 11% 
of the older patients with molecular failure after first consolidation remained in 
complete response (CR) compared with 68% of those with molecular remission. In 
older patients with less intensive therapy, a higher rate of MRD persistence and an 
even poorer outcome can be expected. Therefore, prospective evaluation of MRD 
in older patients is essential to identify those who could benefit from alternative 
experimental treatments, if they were available [18–20, 24].
Some poor prognosis factor applicable to young patients can also be in elderly 
patients, which tells us of the profound impact they have on the biology of the 
disease: the T lineage and the positive Phi chromosome are a pair of these. The 
persistence of positive minimal residual disease is directly related to an increased 
frequency of relapse after remission; it is estimated that young patients with posi-
tive MRD will relapse up to 90% despite receiving intensive CT. We do not have 
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such exact estimates of how much the likelihood of relapse increases when this 
phenomenon occurs in older patients, but it has been estimated in some studies 
that only 11% of these who presented with MRD positive remain in response to the 
disease. Prospective studies that answer these questions are required; however, it 
is necessary to determine MRD in elderly patients as part of the management and 
surveillance protocols [18–20, 23].
In the GMALL study for older patients, we identified comorbidity score, age, 
and performance status before onset of leukemia as prognostic factors with signifi-
cant impact on early mortality. Interestingly, Eastern Cooperative Oncology Group 
(ECOG) status of 2 or more was documented in 7% of the patients before onset of 
leukemia-associated symptoms, but in 38% after onset. The strong correlation of 
performance status with mortality was confirmed by others.
For assessing prognosis in an older ALL patient, it is essential to identify features 
suitable for predicting high risk of early mortality resulting from complications. 
These features can help determine whether a patient has any chance of benefiting 
from intensive treatment. For this purpose, I would consider performance status 
before onset of leukemia, comorbidities, and geriatric assessment and would not 
rely on scores, which are calculated on the basis of historical patient cohorts.
In addition, prognostic factors for response to antileukemic treatment and 
relapse risk must be considered. Because of the lack of confirmed prognostic factors 
for older ALL patients, my approach would be to take known prognostic factors 
for younger patients into consideration, but to focus on MRD evaluation as an 
individual prognostic feature that can cover the impact of biologic factors and also 
treatment intensity, compliance, and other unknown features [21, 26].
In the case of patients with characteristics that could increase the risk of early 
mortality when starting treatment, we must be careful in how to approach this last 
parameter. Several groups dedicated to the analysis of prognostic factors in special 
groups of patients have determined a series of variants and elements that could guide 
the clinic when defining the risk of death of his patient. The GMALL group deter-
mined, in a prospective analysis, that the low physical status (ECOG status of 2 or 
more) prior to the onset of leukemia symptoms correlates with earlier mortality and in 
those patients who already have a diagnosis, this score is seen duplicated at the begin-
ning of the symptomatology. To be able to carry out a complete evaluation of elderly 
patients, it is necessary to apply tools that are useful in most clinical scenarios and that 
confer a high degree of reliability with respect to their predictive power of prognosis. 
It is therefore necessary to apply validated geriatric scores and specific scores of the 
patient for known morbidities in order to achieve the most complete vision possible 
before the diagnosis, in order to guide the treatment and its intensity [21].
In addition to this, we must define what prognostic factors for relapse should 
be applied to these patients after treatment is initiated. Although several of them 
already known with importance in young group can also be applied to elderly 
patients, it should be determined which are more specific for this last group [26].
7.1 Philadelphia ALL
One-quarter of all adults have Philadelphia chromosome, and the incidence 
increases with age. Until the results of recent studies in older patients became avail-
able, most patients with Philadelphia ALL were managed with intensive chemo-
therapy and a tyrosine kinase inhibitor (TKI). Imatinib has improved the CR rate in 
a number of trials to 90% and makes more patients eligible for transplant. Imatinib-
resistant mutations are increasingly reported, and these should be sought in 
relapsed and refractory patients. Dasatinib, which inhibits tyrosine and src kinases, 
holds considerable promise. It may also be effective in CNS disease. There are no 
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randomized comparisons with imatinib, although it is a more potent inhibitor of 
tyrosine kinase in vitro. Recent studies from Italy and France with dasatinib alone in 
older patients have achieved very high remission rates with encouraging short-term 
survival. Good minimal residual disease (MRD) responses correlated with outcome. 
Data regarding the combination of dasatinib and intensive chemotherapy are lack-
ing. It is possible that less conventional induction therapy may be required and that 
allogeneic stem cell transplantation (SCT) may not be mandatory. The remarkable 
effectiveness of TKI therapy, in some studies without chemotherapy or allografting, 
has made us consider de-escalation of therapy, but the long-term results of these 
less intensive approaches are unknown, and allografting is the only known cure. 
The effect of pretransplant MRD status on outcome is unclear [27, 28].
A study of 267 patients (prior to the TKI era) showed allogeneic transplant to 
be superior to chemotherapy, with 44 and 36% surviving 5 years after sibling and 
unrelated donor SCT, respectively. However, only 28% of patients proceeded to a 
CR1 allograft, reducing its impact, and making it important that we improve no 
transplant therapy (and improve access to transplant). The Minneapolis group 
reported 50% survival in 14 patients who received reduced-intensity conditioning 
(RIC) allografts from cord or sibling donors. TKIs were used only for morphologic 
or molecular relapse posttransplant. Studies of TKI posttransplant that examine 
dose, duration, and molecular response are urgently required; this is the subject of 
studies from the German and UK groups that are soon to be reported [28, 29].
7.2 Therapy
The goal of remission induction therapy is to achieve remission without undue 
toxicity with a hematologic recovery that permits further therapy to be promptly 
given. Most regimens use prednisolone or dexamethasone, vincristine, dauno-
rubicin, and asparaginase, with later exposure to cyclophosphamide and Ara-C 
(cytosine arabinoside or cytarabine). Hyper-cyclophosphamide, vincristine, 
doxorubicin, and dexamethasone (CVAD), which does not contain L-asparaginase, 
achieves high complete remission (CR) rates in newly diagnosed patients and 
is a reasonable alternative for induction therapy, but has not been shown to be 
superior to more traditional induction protocols. Dexamethasone is preferred to 
prednisolone because of superior lymphocytotoxicity, better central nervous system 
(CNS) penetration, and fewer thromboembolic events; these data are derived from 
pediatric studies. Poly(ethylene glycol)-asparaginase may be associated with more 
effective asparagine depletion, and this in turn may lead to better outcomes. But 
this requires a randomized comparison. The safety and optimum dose of this drug 
require further study in adults [25, 26, 30].
Population-based study registries give an impression on the overall outcome of 
unselected older ALL patients. Survival rates in patients aged 60 years were 12% at 
5 years in Northern England. For those aged between 65 and 74 years, survival was 
25% in Sweden where outcome further decreased to 10% in patients aged 74 years. 
Five-year OS in patients aged 60–69 years increased from 8% in the years 1992–
2001 to 20% in the years 2002–2011, whereas only marginal improvements from 5 
to 10% were observed for patients aged 70 years. Palliative treatment: some 30–70% 
of the older patients are allocated to palliative therapy mainly due to poor perfor-
mance status at diagnosis. Most studies have shown an advantage of more intensive 
therapy such as higher CR rate, lower early death, better remission duration, and 
median survival compared with palliative treatment according to protocols for adult 
ALL patients. The majority of published data are based on results reported for the 
subgroup of older patients treated within protocols designed for adult ALL in gen-
eral. One large data set confirmed considerable mortality of 18%. The conclusion 
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that induction therapy designed for younger patients may be too intensive for older 
patients. Patients may acquire severe infections, nonpredefined treatment modifi-
cations occur frequently, and treatments may be interrupted or even stopped due 
to severe complications. Overall, potential conclusions from these studies are very 
limited. Prospective studies of protocols for older ALL patients specifically designed 
for older ALL patients have the theoretical aim to provide a chance of cure on the 
one hand and to limit toxicity, early mortality, and hospitalization duration on the 
other hand, and the therapy maintains as much quality of life as possible. One cen-
tral question is whether and/or which anthracycline has to be included in induction 
regimens for older patients, because these drugs contribute considerably to bone 
marrow toxicity [5, 6, 15, 31]. One approach is the use of idarubicin in induction, 
based on a potentially lower cardiac and hepatic toxicity. The results of liposomal 
anthracyclines in elderly ALL are not convincing so far. Asparaginase is an essential 
compound in the treatment of ALL. The PETHEMA group reported the results of 
an intensive induction regimen, including asparaginase for older ALL patients. The 
early death rate, mainly due to infection, was rather high (36%) and was reduced 
after omission of asparaginase and cyclophosphamide. A high early mortality rate 
(29%) and a number of complications including infections (71%), cardiac toxic-
ity (18%), and hyperglycemia (24%) were also observed in another trial utilizing 
asparaginase during induction therapy. Furthermore, a pediatric-based regimen 
using pegylated asparaginase during induction in older patients revealed grade 3–4 
bilirubin increases in 33% of the patients. Thrombosis and pancreatitis are other 
relevant toxicities of asparaginase. Altogether, there is some evidence that the use 
of asparaginase during induction therapy may be associated with increased risks 
in older patients. Therefore, it would be advisable to start asparaginase in older 
patients later during consolidation. The majority of complications in older ALL 
patients is observed during induction; thus, there is still space for intensification of 
consolidation therapy [14, 23, 32]. Based on this assumption, a consensus treat-
ment protocol for older patients with ALL was defined by the European Working 
Group for Adult ALL (EWALL). The 4-week, pediatric-based induction comprises 
dexamethasone, vincristine, and idarubicin in phase 1 and cyclophosphamide and 
cytarabine in phase 2. Consolidation consists of six alternating cycles with inter-
mediate-dose methotrexate combined with asparaginase and high-dose cytarabine, 
followed by maintenance. The median age at enrollment was 66 (56–73) years with 
22% at 70 years. The incidence of grade 3–4 cytopenias was 90%, and infections 
during phases 1 and 2 of induction occurred in 16 and 25% of the patients, respec-
tively. Toxicities were less pronounced during consolidation, and asparaginase was 
well tolerated. CR, survival, and continuous CR rates after 1 year were 85, 61, and 
49%, respectively. Another report based on the same backbone showed CR rates of 
74% and an OS of 30% at 2 years [18, 20, 33]. The authors also observed grade 3–4 
infections in 62% of the patients during induction therapy with a median duration 
of neutropenia of 24 days, whereas consolidation was far better tolerated even 
when including the use of asparaginase [18, 20, 23, 34]. The GMALL has conducted 
thus far the largest prospective trial specifically designed for older patients with 
Ph/BCR–ABL-negative ALL. Pediatric (Berlin-Frankfurt Munster)-based, dose-
reduced induction therapy with idarubicin, dexamethasone, vincristine, cyclophos-
phamide, and cytarabine was followed by alternating consolidation cycles for 1 year 
and maintenance. Patients with CD201 ALL received rituximab in combination 
with chemotherapy. The median age of this cohort was 67 (55–85) years. In 268 
patients, the CR rate was 76%, early death rate 14%, mortality in CR 6%, continu-
ous remission 32%, and survival 23% at 5 years. Patients aged 75 years with an 
Eastern Cooperative Oncology Group performance status below 2 had an 86% CR 
rate, 10% early death, and 36% survival at 3 years. Interestingly, the replacement 
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of triple intrathecal therapy during induction resulted in a reduced early mortality. 
Moderate intensification of consolidation as in the EWALL regimen, with inclusion 
of high-dose cytarabine and intermediate-dose methotrexate and native Escherichia 
coli asparaginase was tolerated [24, 26, 30].
Overall, mortality in CR was 6% only. Overall, pediatric-based regimens in ALL are 
undoubtedly successful and should be scheduled with prospectively defined adapta-
tions with respect to tolerability in older patients. The most important modification of 
induction therapy in older patients is probably the omission of asparaginase, and the 
flexible, reduced dose of anthracyclines. In consolidation, intensified treatment should 
be attempted, and during this treatment phase, even asparaginase may be surprisingly 
well tolerated at moderate doses [29, 34]. In this treatment, patients aged 55–70 years 
and 70–75 years tolerated pegylated asparaginase at dose levels of 1000 and 500 U/m2, 
respectively, as single-drug interim therapy during consolidation. Combination with 
high-dose methotrexate will be further explored and careful use is recommended in 
patients with preexisting liver disease. [23, 24, 26, 30, 35]. Nowadays, older patients with 
Ph+ ALL may have a better chance to achieve a CR than patients with Ph+ ALL. The 
use of TKIs upfront is most promising. The GMALL conducted a first randomized 
study to evaluate the efficacy of imatinib single-drug induction compared with 
chemotherapy. The remission rates were 96 and 50%, respectively. Only 11% of the 
patients achieved a molecular remission. A follow-up including nonrandomized data 
yielded a CR rate of 88% in 121 patients, together with a 22% 5-year survival rate. The 
Gruppo Italiano Malattie Ematologiche dell’Adulto trial used imatinib (800 mg) with 
prednisone for induction, followed by imatinib single-drug treatment. The CR rate, 
survival, and disease-free survival were 100, 74, and 48%, respectively, after 1 year. A 
subsequent trial with dasatinib (140 mg) and prednisone, followed by dasatinib single-
drug treatment, was not specifically designed for older patients (range, 24–76 years). 
The CR rate was 92% and survival was 69% at 20 months. Postremission therapy was 
at the discretion of the treating physician and 14 of 19 patients with TKI monotherapy 
relapsed with a high frequency of T315I mutations [31, 33, 35]. Another trial was based 
on a rotating schedule with 6 weeks of nilotinib treatment alternating with imatinib 
treatment. In 39 patients, the CR rate was 94% and the OS at 1 year was 79%. Nearly, 
all relapsed patients in this trial showed mutations associated with TKI resistance. 
The largest prospective study so far in older patients with Ph+ ALL used an EWALL 
chemotherapy backbone with vincristine, dexamethasone, and dasatinib (140 mg) 
for induction. Consolidation and maintenance according to the EWALL backbone 
was combined with intermittent dasatinib applications. In 71 patients, the CR rate was 
96%. The regimen was feasible and the survival after 5 years of follow-up was 36%, 
which is promising. Persistent MRD above 0.1% after induction and consolidation was 
associated with poorer remission duration of only 5 months. A subsequent EWALL 
trial with a similar backbone but with nilotinib (400 mg twice daily) instead of dasat-
inib was started subsequently. Again, a high CR rate of 97% was reported. About 30% 
of patients achieved a complete molecular remission after induction. Overall, there is 
increasing evidence that second-generation TKIs in combination with dose-reduced 
chemotherapy can induce very high CR rates with low mortality in older patients. 
The rate of molecular remissions appears to be higher compared with imatinib-based 
regimens. Moderate intensive consolidation therapies in combination with TKIs are 
tolerated well. Long-term results have to be assessed after 5 or more years and show a 
still high rate of relapses. New approaches may include reduced intensity stem  
cell transplantation (SCT), MRD-based change of TKIs, or use of new immunothera-
pies [23, 36, 37].
In other study, 127 patients with ALL were enrolled including 26 elderly 
patients (≥60 years) and 101 younger adult patients (<60 years). The median 
follow-up durations were 6.0 months (range, 0.4–113.2) in the elderly patients 
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and 21.7 months (range, 1.0–122.7) in the younger patients. The median age of the 
younger patients with ALL was 30 years (range, 15–58), whereas that of the elderly 
patients with ALL was 65 years (range, 60–82). No significant differences in the 
baseline characteristics of the two groups were observed, except in history of malig-
nancy; a larger portion of elderly patients with ALL had a history of malignancy 
(p = 0.001). The composition of ALL subtypes and the frequencies of Ph+ status 
were not statistically significant between the two groups. The peripheral blood 
sample laboratory findings showed more severe anemia in younger adult patients 
with ALL than in the elderly patients (p = 0.023); of 26 elderly patients with ALL, 
abnormal karyotypes were found in 14 patients (53.8%) [38, 39].
All patients, with the exception of two elderly patients who received supportive care 
only, received induction chemotherapy. About half of the elderly patients (12 patients, 
46.2%) received the VPDL regimen as an induction therapy. Five elderly patients 
(19.2%) were administered the VPD regimen, and one (3.8%) was administered the 
hyper-CVAD (cyclophosphamide 300 mg/m2, D1–3; vincristine 2 mg D4,11; Adriamycin 
50 mg/m2, D4; dexamethasone 40 mg D1–4, D11–14) regimen. The overall CR rate was 
much higher in the younger adult patients than that in the elderly patients (94.1 vs. 57.7%, 
p < 0.001). Early mortality within 3 months from the start of induction chemotherapy 
was remarkably higher in the elderly patients (26.9% vs. 5.0%, p = 0.003).
The median number of postremission consolidation therapy sessions was three 
(range, 1–5) in the elderly patients with ALL. The regimen in the elderly patients 
was vincristine and prednisolone in seven patients. Two patients received only ima-
tinib due to severe comorbidities. One patient received the CALGB 9251 regimen, 
and the other patient received nonmyeloablative hematopoietic stem cell transplan-
tation (HSCT) from a matched sibling donor. Of 15 elderly patients who achieved 
CR, only 11 received postremission therapy. The overall nondisease-related mortal-
ity rate in the elderly patients was higher than that in the younger adult patients.
Cumulative hazards of disease-related and nondisease-related mortality in 
younger adult patients (<60 years) with acute lymphoblastic leukemia (ALL) and in 
elderly patients (≥60 years) with ALL (p = 0.001 and 0.12, respectively).
The median OS of the younger patients was 26.3 months (95% confidence inter-
val [CI], 19.6–33.0), whereas that of the elderly patients was 10.3 months (95% CI, 
3.5–17.2) (p = 0.003). The survival difference according to age was not reproduced 
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in the subpopulation of patients with Ph-positive ALL (data not shown), but was 
consistently found in the patients with Ph-negative ALL.
A. Overall survival (OS) of elderly and younger adult patients with acute lympho-
blastic leukemia (ALL): OS of elderly patients with ALL (≥60 year) was shorter 
than that of younger adult patients with ALL (<60 year) (median OS 10.3 vs. 
26.3 months, respectively, p = 0.003).
B. OS of the elderly and younger adult patients with Philadelphia chromosome 
(Ph)-negative ALL: OS of the elderly patients with Ph-negative ALL (≥60 year) 
was shorter than that of adult patients with Ph-negative ALL (<60 year) 
(median OS, 10.3 vs. 29.2 months, respectively, p = 0.01).
C. OS according to complete remission in elderly patients with ALL: OS of elderly 
patients with complete remission was longer than that of elderly patients with-
out complete remission (median OS, 13.1 vs. 2.6 months, p = 0.001).
D. OS according to age (60–69 vs. ≥70 years) in elderly patients with ALL: OS of 
elderly patients aged 70 years or more was not significantly different from that of 
the other elderly patients (median OS, 11.2 vs. 3.7 months, p = 0.073) [40, 41].
8. Survival analysis for elderly patients with ALL
Among the elderly patients, the patients who achieved CR1 (CR after the first 
induction chemotherapy) showed significantly longer survival compared with those 
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who did not achieve CR1 (median OS, 13.1 vs. 2.6 months; p = 0.001). Furthermore, 
CR1 was the only independent prognostic factor for OS in elderly patients with ALL 
(p = 0.001). Although the OS of elderly patients aged 60–69 tended to be longer 
than that of those aged 70 or over, the difference did not reach statistical significance 
(median OS, 11.2 vs. 3.7 months; p = 0.073).
In the survival analysis using the factors at the initial ALL diagnosis, the prob-
able poor prognostic factors for CR were age ≥ 70 years (relative rate of remission 
[RR], 0.14; 95% CI, 0.013–1.45; p = 0.098) and leukocytosis (≥30,000/μL) (RR, 
6.00; 95% CI, 0.93–38.63; p = 0.059). T-cell lineage and the presence of lymphade-
nopathy were significant factors in poor prognosis for OS in the univariate analysis 
(hazard ratio [HR], 3.11 and 3.14; 95% CI, 1.14–9.34, and 1.01–9.99; p = 0.033 and 
0.041, respectively). T-cell lineage and Ph-positive status tended to increase the 
HR for leukemia free survival (LFS) (HR, 8.49 and 4.49; 95% CI, 0.53–135.82 and 
0.8–25.21; p = 0.069 and 0.064, respectively).
Univariate analysis for complete remission, overall survival, and leukemia-free 
survival in elderly patients with ALL (≥60 year) (n = 26).
ALL, acute lymphoblastic leukemia; RR, relative rate of remission; CI, confidence 
interval; HR, hazard ratio; Ph, Philadelphia chromosome; WBC, white blood cell.
The low response to chemotherapy in the elderly patients with ALL could be 
related to several factors. The first factor may be chemotherapy intensity. Intensified 
combination induction chemotherapy can result in an improvement in the CR pro-
portion, and high-dose postremission methotrexate (MTX) or cytarabine therapy 
is effective for treating adult ALL. However, most elderly patients with ALL in our 
study could not receive the postremission therapy after the induction therapy with 
a standard or reduced dose and also could not be treated with intensified postremis-
sion regimens such as cyclophosphamide or MTX, though they received postremis-
sion therapy. The second factor may be drug-resistance mechanisms such as the 
presence of multidrug-resistance gene 1 and multidrug-resistance-related protein.
Although intensified induction chemotherapy was not introduced, and pos-
tremission therapy was not performed appropriately in most elderly patients with 
ALL, the survival benefit was definite in the patients who achieved CR. Our study 
did not show a statistical difference in nondisease-related mortality rates between 
the elderly and younger adult groups. However, the actual risk of nondisease-
related mortality might be significantly higher in the elderly patients considering 
that only a few patients could receive highly toxic therapy such as HSCT, and our 
results indicated that about half (43.8%) of nondisease-related mortality was 
related to HSCT in the younger adult patients with ALL [40–43].
8.1 New treatment options in older patients with ALL
ALL blasts express a number of antigens, such as CD33, CD22, CD19, and CD52, 
which could be targets for antibody therapy. The majority of older patients suffer 
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from B-precursor ALL. In this subtype, approximately half of the patients show 
CD20 expression on their blast cells. In younger patients with CD20+ ALL, the first 
promising data for the combination of chemotherapy and rituximab have been 
reported. Outcome of older patients could be hampered by a higher mortality due to 
infections in CR, which underlines the need for intensive supportive care for older 
patients throughout the entire treatment period.
A great majority of cases with ALL in elderly patient correspond to B-precursor 
lineage, one of the characteristics of this lineage is the expression of CD20 on its 
surface, which makes it susceptible to treatments focused on this marker, such 
as rituximab, this treatment approach has already shown to be highly effective in 
young patients, which could be transposed to the population over 65 years of age.
A promising new approach is the administration of a bispecific CD19 antibody, 
blinatumomab, which has the potential to engage cytotoxic T cells in patients for 
lysis of CD19+ leukemia cells. In 19 patients with refractory disease, defined as 
hematologic remission with persistent MRD after intensive chemotherapy, the 
molecular remission rate was 84%. A number of older patients who were not able 
to receive an SCT remained in remission for more than 1 year. More recently, a CR 
rate of 68% was reported for relapsed ALL. All patients with CR also achieved a 
molecular CR. Treatment with the final dosing regimen was well tolerated, and a 
number of older patients experienced a benefit. The CD22 directed, calicheamicin-
conjugated antibody inotuzumab induced 18% CRs and 39% marrow CRs in 
relapsed CD22+ ALL. Toxicity appeared to be manageable, and the mortality of 
4% within 4 weeks was moderate. Successful future use of antibody treatment will 
certainly depend on well-designed combination regimens with chemotherapy that 
aim to achieve long-term responses, particularly in older ALL patients.
In recent years, there have been advances and new therapeutic options in the 
management of ALL, one of the most promising is immunotherapy, specifically 
bispecific antibodies, the first of which useful information was disclosed was 
blinatumomab, this antibody that acts by binding to T lymphocytes, activating 
them and forcing them to destroy CD19 receptor expressing cells, such as blasts, 
already has multiple studies in various population groups that demonstrate their 
effectiveness against the disease, achieving significant response rates (84%) and 
negativization of the MRD. Another new specific antibody against the CD22 recep-
tor, inotuzumab, has also been shown to be effective, at least in its initial studies, 
with a tolerable safety profile. The great advantage of these new treatments is that 
they do not confer the implicit risk in chemotherapy; however, there are no studies 
specifically in elderly patients.
Several other new drugs are of interest for optimizing treatment in older ALL 
patients. Although the number of older patients with T-ALL is low, the use of 
nelarabine is of interest after promising results and acceptable toxicity in relapsed 
T-ALL including older patients. Liposomal cytarabine for intrathecal application 
showed activity and tolerability in CNS relapse of ALL, although in combination 
with systemic neurotoxic regimens, severe toxicities may be observed. The use of 
liposomal cytarabine in prophylaxis of CNS relapse is of interest, particularly in 
older patients, since it allows reduction of the number of intrathecal injections and 
may induce fewer systemic toxicities compared to conventional intrathecal therapy.
Other drugs of current interest include nelarabine, indicated for use in cases 
of T-ALL. The prophylactic treatment to CNS has also had new protagonists in its 
field, liposomal cytarabine is one of these; this drug used for both prophylaxis and 
management of relapse to CNS has shown to be safe, although when combined 
with other neurotoxic agents, there is considerable toxicity. Despite this, safety 
is comparable to that presented by conventional cytarabine, with a higher rate of 
effectiveness.
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Liposomal vincristine is another drug of interest, particularly in older patients. 
Results are still pending on the major question of whether liposomal encapsula-
tion allows a higher dose intensity with lower risk of neurotoxicity. Bendamustine 
could be of interest, since it has shown limited toxicity and favorable results in 
older patients with B-cell lymphoma. New drugs with different mechanisms of 
action may, in the future, be used in combination with chemotherapy, such as 
proteasome inhibitors, histone-deacetylase inhibitors, hypomethylating agents, or 
targeted drugs such as Flt3 inhibitors or Jak2-inhibitors in defined subgroups of 
ALL. Currently, these compounds are either available in clinical trials or could be 
considered in individual patients with poor response to standard chemotherapy, 
including patients with molecular failure [12, 23, 43, 44].
Bendamustine and liposomal vincristine are new tools already known, the first 
one, a drug developed in the 1960s, has shown its effectiveness in various studies 
in the management of ALL and other lymphoproliferative disorders, with adequate 
safety in elderly patients. New mechanisms of action must be explored in order to 
give variety to the maneuvers against the disease. The study of new prognostic and 
risk markers that can be targeted by these drugs is crucial for their development. 
Currently, a large number of studies are underway in the world, both with new 
combinations of already known drugs and with novel molecules applicable to ALL 
[12, 23, 43, 44].
9. Conclusion
All older ALL patients need a comprehensive diagnostic classification, includ-
ing, at least, immunophenotyping, molecular diagnostics, and setup of an assay 
for MRD evaluation. The identification of Ph+ ALL is crucial since, even in very 
old and frail patients, TKIs induce a high CR rate with reasonable durability. 
Furthermore, the biological characterization of older ALL patients needs to be 
improved. Biobanking for future scientific investigations within clinical trials 
should therefore be standard in older as it is in younger patients.
Altogether, in older as in younger patients, a pediatric-based induction strategy 
is recommendable in Ph− ALL. Dose reductions for anthracyclines are essential, 
and asparaginase during induction cannot be recommended outside of clinical tri-
als. Dexamethasone appears to increase efficacy in younger patients, but prolonged 
use should be avoided. For fit older patients, consolidation chemotherapy may be 
intensified. Moderate-dose consolidation, including methotrexate, cytarabine, 
and reinduction therapy, appears to be feasible, and maintenance treatment is an 
essential treatment element.
In unfit older patients, a dose-reduced induction therapy is recommended with 
the aim of controlling and achieving a prolonged low-level disease. ALL-specific 
approaches should be considered, including vincristine, steroids, intrathecal 
therapy, and maintenance with mercaptopurine and methotrexate. Many physi-
cians have more experience with older AML patients; however, there is no rationale 
for using AML regimens such as low-dose cytarabine or hydroxyurea in ALL.
When they are available, targeted drugs such as nelarabine, monoclonal antibod-
ies, or other new drugs with potentially reduced or alternative toxicity should be 
added to treatment strategies in older patients, preferably in clinical trials. Since many 
of these compounds are used off-label, it may be useful to make the indication based 
on persistent MRD, which, in addition, offers a chance to evaluate effects immedi-
ately. Treatment options may change as soon as new drugs or strategies become avail-
able. With effective drugs for prolonged maintenance, it may be possible to further 
reduce intensity of induction therapy and avoid early mortality in unfit patients.
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In Ph+ ALL, it is still not clear whether further reduced induction chemotherapy 
adds an effect to TKI therapy and which inhibitor is preferable. I favor a combina-
tion therapy. Moderate dose consolidation and maintenance should be offered. 
Patients should be considered as candidates for RIC SCT.
Whereas full-conditioning regimens before SCT are clearly not recommended, 
RIC SCT is an option in older patients. For indication, it will be crucial to define 
prognostic factors. Because persistence of MRD is one of the most important risk 
factors, MRD evaluation should take place in older patients to identify those who 
could benefit from experimental therapies or SCT. This also applies to Ph+ ALL 
regarding the option of changing the TKI.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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